On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Vivek Subbiah

ResearcherPublications, citations & collaboration network

Vivek Subbiah is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Vivek Subbiah have?

ScholarIQindexed works

Vivek Subbiah has 1,436 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Vivek Subbiah have?

ScholarIQcitation count

Vivek Subbiah has 32,569 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Vivek Subbiah?

ScholarIQh-index

Vivek Subbiah has an h-index of 80 in OpenAlex.

What is the i10-index of Vivek Subbiah?

ScholarIQi10-index

Vivek Subbiah has an i10-index of 409 in OpenAlex.

What is the ORCID of Vivek Subbiah?

ScholarIQorcid

The ORCID for Vivek Subbiah is on the source record.

What is the OpenAlex record for Vivek Subbiah?

ScholarIQopenalex

The OpenAlex for Vivek Subbiah is on the source record.

What are the most-cited papers on Vivek Subbiah?

ScholarIQmost cited works
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Herbert H. Loong, Melissa L. Johnson, Justin F. Gainor, Caroline E. McCoach, Oliver Gautschi, Benjamin Besse, Byoung Chul Cho, Nir Peled, Jared Weiss, Yu-Jung Kim, Yuichiro Ohe, Makoto Nishio, Keunchil Park, Jyoti D. Patel, Takashi Seto, Tomohiro Sakamoto, Ezra Y. Rosen, Manisha H. Shah, Fabrice Barlési, Philippe A. Cassier, Lyudmila Bazhenova, Filippo de Braud, Elena Garralda, Vamsidhar Velcheti, Miyako Satouchi, Kadoaki Ohashi, Nathan A. Pennell, Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah
New England Journal of Medicine. 2020842 CitationsOPEN ACCESS
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
Lori J. Wirth, Eric J. Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen H. Lorch, Francis P. Worden, Marcia S. Brose, Jyoti D. Patel, Sophie Leboulleux, Yann Godbert, Fabrice Barlési, John C. Morris, Taofeek K. Owonikoko, Daniel S.W. Tan, Oliver Gautschi, Jared Weiss, Christelle de la Fouchardière, Mark E. Burkard, Janessa Laskin, Matthew H. Taylor, Matthias Kroiß, Jacques Médioni, Jonathan W. Goldman, Todd M. Bauer, Benjamin Levy, Viola W. Zhu, Nehal J. Lakhani, Víctor Moreno, Kevin Ebata, Michele Nguyen, Dana Heirich, Edward Y. Zhu, Xin Huang, Luxi Yang, Jennifer Kherani, S. Michael Rothenberg, Alexander Drilon, Vivek Subbiah, Manisha H. Shah, Maria E. Cabanillas
New England Journal of Medicine. 2020788 CitationsOPEN ACCESS
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah, Ulrik Lassen, Elena Élez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W. Prager, Richard Greil, Alexander Stein, Angelica Fasolo, Jan H.M. Schellens, Patrick Y. Wen, Kert Viele, Aislyn Boran, Eduard Gasal, Paul Burgess, Palanichamy Ilankumaran, Zev A. Wainberg
The Lancet Oncology. 2020531 Citations
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo, Vivek Subbiah, Benjamin Besse, Víctor Moreno, Rafael López‐López, María Ángeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Khalil Zaman, Valentina Boni, Jennifer Arrondeau, Maite Martínez, Jean‐Pierre Delord, Ahmad Awada, Rebecca Kristeleit, M.E. Olmedo, Luciano Wannesson, Javier Valdivia, María Jesús Rubio, Antonio Antón, John Sarantopoulos, Sant P. Chawla, Joaquín Mosquera, M. D’Arcangelo, Armando Santoro, Víctor M. Villalobos, Jacob Sands, Luis Paz‐Ares
The Lancet Oncology. 2020476 Citations
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik, Robert C. Doebele, Philippe A. Cassier, Gilberto Lopes, Daniel S.W. Tan, Elena Garralda, Luis Paz‐Ares, Byoung Chul Cho, Shirish M. Gadgeel, Michael Thomas, Stephen V. Liu, Matthew H. Taylor, Aaron S. Mansfield, Viola W. Zhu, Corinne Clifford, Hui Zhang, Michael Palmer, Jennifer Green, Christopher D. Turner, Vivek Subbiah
The Lancet Oncology. 2021451 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account